Searched for
AUROBINDO PHARMA Q2
Strong macro show takes shape in Q2 before festive rushIndia's economy is experiencing significant growth, highlighted by a 14.7% increase in goods and services tax collections in September. Car...- Retail leasing moderated by 7.3% quarter-on-quarterIndia’s retail real estate sector showed active occupier demand with gross leasing volume reaching 2.22 million square feet. Main streets r...
- Tata Motors Passenger Vehicles sales rise 15% in September to 70,210 unitsTata Motors Passenger Vehicles Ltd reported its best-ever quarter in Q2 FY27, with total sales rising significantly. The company's electric...
- NTPC power generation grows 13% to 118 bn units in Q2; coal dispatch up 28%NTPC has achieved a significant 13 percent year-on-year growth in power generation for the July-September quarter. The power generation inc...
- Tata Motors PV shares fall over 3% despite 40% Q2 sales growth; Nifty Auto index down over 4%Tata Motors Passenger Vehicles shares dipped on Thursday despite a 40% year-on-year rise in Q2 FY27 sales, while the Nifty Auto index decli...
- RIL Q2 Results: Nuvama sees 17% EBITDA growth, led by O2C biz. Here’s what to expectReliance Industries is expected to report 17% year-on-year growth in Q2FY27 EBITDA to Rs 53,700 crore, led by stronger refining margins and...
- Stocks in news: Infosys, HDFC Bank, Jio Financial, IRFC, NCC and Blue DartIndian equity benchmarks experienced a decline over two sessions due to profit booking and rising oil prices. The Nifty 50 index closed dow...
- Buoyant Q2 demand for consumer goods lifts festive sales outlookConsumer demand in India saw significant growth during the July-September quarter, particularly in appliances and FMCGs. Sales of air condi...
- Globalisation 2.0, can it be furrowed home?Indian corporations are making bold strides abroad, with Essar establishing a massive $15 billion steel complex in Iowa. Notable companies ...
- Q2 earnings: Can India Inc repeat Q1, or will Q3 erase the base-effect tailwind?India Inc is likely to see a dip in earnings performance for Q2 in comparison to Q1, with analysts forecasting a growth slowdown of roughly...
- TCS, Wipro, other IT stocks rebound up to 6%, snapping 8-day losing streak. Why is Jefferies cautious?IT stocks rebounded on Wednesday, with TCS, Wipro and Coforge snapping an eight-session losing streak. The Nifty IT index rose nearly 3%, a...
- Ahead of Market: 10 things that will decide stock market action on WednesdayNifty’s indicative price plunged 2% in two seconds during the closing auction session on monthly expiry, before recovering sharply. Analyst...
- Americans are struggling to find affordable used cars: Here's what a $10,000-$15,000 budget gets you in 2026Used-car buyers are encountering obstacles as they search for older models that come with increased mileage and higher prices. The pool of ...
- Two Trades for Today: 2 mid-cap pharma stocks, one for a rise of 6.2%, and the other for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platformAnupam Rasayan India Limited has finalised its acquisition of a controlling interest in Bliss GVS Pharma, marking a strategic expansion int...
- Sun Pharma, Aurobindo Pharma, other stocks in focus as Trump exempts India from 100% tariffs on some speciality drugsIndian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other countries from 100% ...
- Shein returns to profit in second quarter, but warns of uncertain second halfAn increase in total orders fulfilled supported a more than 20% sequential jump in Shein's second-quarter net revenue, although the Iran co...
- Home sales increase by 3% annually during July-SeptemberHome sales in the top seven cities have shown signs of recovery during the third quarter of 2026. Total sales increased by 3% compared to t...
- Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers al...
- JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...
Load More
